THE CANCER DRUG DEVELOPMENT FORUM

FACILITATE. DEBATE. ACTIVATE. INNOVATE.

Promoting Multi-Stakeholder Collaboration to Advance Oncology Therapeutics.
OUR MISSION

The Cancer Drug Development Forum (CDDF) is the leading non-competitive drug development platform in Europe whose sole objective is to stimulate advancement in cancer drug development and access.

HOW WE ADVANCE OUR MISSION

The CDDF provides a unique platform to facilitate collaboration between stakeholders to increase efficiency in cancer drug development.

Our integrative approach aims to bring together leading voices from academia, the pharmaceutical industry, regulatory authorities, health technology assessors, policymakers, and patient groups to improve cancer treatment.

INITIATIVES

For years, the Cancer Drug Development Forum (CDDF) has focused on developing initiatives that accelerate effective drug development in oncology treatment and shorten time to market, and time to patient access.

CDDF offers workshops, conferences and webinars that bring stakeholders involved in cancer drug development into a productive dialogue in a neutral, non-competitive space.

CDDF holds multiple activities and initiatives in collaboration with regulators from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) and other regulatory agencies, academic researchers from around the globe, pharmaceutical companies, and patient advocates.

The Cancer Drug Development Forum (CDDF) Spring Conference is a unique annual meeting. This multi-stakeholder, interactive 3-day meeting offers plenary lectures with moderated discussions, including case studies and networking opportunities.

The responsive nature of the CDDF platform means that programs can be quickly initiated or adapted to reflect current and pressing issues. Following the outbreak of the COVID-19 pandemic, CDDF rapidly organised a webinar to discuss the potential impact of the virus on both cancer care delivery and clinical trial performance.

Since its inception, CDDF has proved to be a visionary force within the cancer drug development field addressing topics such as immuno-oncology, the use of real-world data in cancer drug development, or improving outcomes for children and adolescents with cancer through the ACCELERATE platform launched in 2013.

The CDDF continues to pioneer progress in cancer drug treatments by exploring the potential impact of digital health and artificial intelligence on cancer patients at forthcoming workshops.

CDDF publishes reports prepared from workshops discussions, conference presentations and lecture briefings to increase knowledge of the challenges and opportunities in cancer drug development.
CDDF LEADERSHIP
The CDDF is governed by a rotating board of directors dedicated to the development of cancer drugs.

Representing a range of perspectives within the drug development process, these distinguished academics are experienced pre-clinical and clinical investigators, medical oncologists, statisticians, and immunologists, who have experience working within regulatory agencies, the pharmaceutical industry and patient advocacy.

The chairperson and directors are elected for a period of three years.

CDDF BOARD OF DIRECTORS

Prof. John Smyth
Chairperson

Prof. Ruth Plummer
Deputy Chairperson

Prof. Axel Glasmacher
Treasurer

Prof. Jaap Verweij
Board Member and Managing Director

Prof. Francesco De Lorenzo
Board Member

Prof. Eva Skovlund
Board Member

Dr Catarina Edfjäll
Board Member

CDDF OFFICE
CDDF staff members oversee the day to day running of the organisation. The head office is located in Brussels, Belgium.

Marjorie Recorbet
Director of operations

Hyunmin Park
Projects coordinator
**OBJECTIVES**

Analyse the important role real-world data (RWD) can play as a source of supplementary, real-world evidence (RWE) for healthcare decision-making.

Identify key opportunities and challenges in RWD proposals facilitating healthcare decision-making in oncology.

Share experiences and discuss methodological issues for obtaining RWE that is fit for regulatory decision-making and access.

Analyse issues concerning RWD quality, quantity, ownership and privacy.

The importance of prospective RWD collection using the appropriate methodology to minimise biases; the role of cancer registries in collecting robust RWD.

The need to identify ways to collaborate and leverage RWE across countries while complying with the General Data Protection Regulation (GDPR).

The need to establish new methods and study designs for real-world research trials.

Calls for action to:

- Define categories of RWD evidence-levels.
- Use different approaches for rare and common cancers.
- Harmonise efforts in RWD approaches.
- Involve patients as key stakeholders.

---

**RECENT CDDF ACTIVITIES**

The CDDF yearly conference and workshops focus on currently identified issues in cancer care and foster an exchange of expertise to accelerate and deliver cancer treatments.

**CONFERENCE**

CDDF 11TH YEARLY SPRING CONFERENCE

THE NETHERLANDS | 10-12 FEBRUARY 2020

**OBJECTIVES**

Understanding the relevance of individual components in combination therapies.

Analysis of progress made in previous CDDF workshop issues: biomarkers; patient access and involvement; Minimal Residual Disease; use of real-world data in drug development.

Understanding advances in, and the need for, innovation and collaboration in tumour agnostic drug-development.

Addressing regulation, progress and challenges in cellular therapies including car-T cell therapies.

Addressing regulatory guidance: EMA regulatory strategy 2025; envisioning product development for 2025; Industry perspectives on innovation and current topics in oncology.

**KEY TAKE-HOME MESSAGES**

The need to identify the best way forward to speed up drug approval whilst ensuring patient efficiency and safety and avoiding patient discrimination due to limited data on endpoints.

The need to consider the best interests of patients in the drug innovation mission. Agencies must ensure that the benefit-risk balance is positive.

Potential advantages and challenges of project Orbis.

---

**WORKSHOP**

THE USE OF REAL-WORLD DATA TO OPTIMISE ONCOLOGY DRUG DEVELOPMENT AND ACCESS

AMSTERDAM, THE NETHERLANDS | 21-22 NOVEMBER 2019

**OBJECTIVES**

Analyse the important role real-world data (RWD) can play as a source of supplementary, real-world evidence (RWE) for healthcare decision-making.

Identify key opportunities and challenges in RWD proposals facilitating healthcare decision-making in oncology.

Share experiences and discuss methodological issues for obtaining RWE that is fit for regulatory decision-making and access.

Analyse issues concerning RWD quality, quantity, ownership and privacy.

**KEY TAKE-HOME MESSAGES**

The importance of prospective RWD collection using the appropriate methodology to minimise biases; the role of cancer registries in collecting robust RWD.

The need to identify ways to collaborate and leverage RWE across countries while complying with the General Data Protection Regulation (GDPR).

The need to establish new methods and study designs for real-world research trials.

Calls for action to:

- Define categories of RWD evidence-levels.
- Use different approaches for rare and common cancers.
- Harmonise efforts in RWD approaches.
- Involve patients as key stakeholders.
OBJECTIVES
Discuss the opportunities and challenges of incorporating patient-relevant evidence into oncology drug development.
Discuss the drug approval and appraisal process from a range of perspectives: academia, the pharmaceutical industry, regulatory authorities, health technology assessors and patients.

KEY TAKE-HOME MESSAGES
Calls for action to:
- Raise awareness of the benefits of clinical trials and facilitate patient access to clinical trials.
- Better collect, document and communicate data on patient-reported outcomes (PROs).
- Collaborate on and synchronise methodologies.
- Develop stakeholder policies on patient involvement.
- Improve informed decision-making and quality of care for patients standardising outcome assessments.

CDDF AGENDA 2020-2021
2020-21 events focus on current and future challenges impacting cancer drug development

WEBINAR
TREATMENT OF CANCER PATIENTS DURING THE SARS-COV2 PANDEMIC: IMPLICATIONS FOR CLINICAL TRIALS.
WEBINAR | 2 APRIL 2020
Oncology clinical trial performance has been severely affected by the COVID-19 pandemic. Most researchers have stopped recruitment and the reduction in currently available standard treatments for cancer patients, has also rendered trials outcomes difficult to assess. Regulatory agencies have already published guidance documents that call for revised risk assessment.

Prof. Marie von Lilienfeld-Toal is the lead author of the German, Austrian and Swiss Guidelines on the impact of COVID-19 on clinical trials providing recommendations to the European Hematology Association (EHA) Scientific Working Group Infections in Hematology. Prof. Lilienfeld-Toal presented these recommendations followed by an opportunity for a question and answer session with the public.

FORTHCOMING WEBINARS
The CDDF plans a series of upcoming webinars throughout the year to further address issues surrounding the impact of COVID-19 on cancer treatment and drug approval, HTA performance in post-approval period and also the use of immunosuppressive agents in oncology.
Address the latest and future challenges of innovative oncology drug development with a special emphasis on patient access, cancer drug development in a global setting, advances in imaging and regulatory guidance on oncology drug development.

To understand the current landscape of use to digital tools in cancer drug development

To explore regulatory aspects, challenges and plans for formal registration of digital tools from trial data

To learn about the various digital options to support trials and improve data collection and outcomes

CDDF INDUSTRY PARTNERS PLATFORM

WHAT IS THE CDDF INDUSTRY PARTNERS PLATFORM?
The CDDF Industry Partners Platform is composed of large and SME partners from the pharmaceutical industry who support the CDDF in its mission to establish a neutral space for stakeholders to facilitate discussion on innovative drug development in oncology.

The Industry Partners Platform acts as an advisory body within CDDF and supports the association in compliance with all relevant regulations and in a manner consistent with the non-competitive, non-commercial platform that CDDF offers to all stakeholders.

CONTRIBUTE TO THE DEVELOPMENT OF CANCER DRUGS AND TREATMENT

Stimulate advancement in oncology treatment and delivery

Identify and overcome challenges in the development of cancer drugs

Improve product time to market for new treatments
ANNUAL CONTRIBUTION

CDDF funding is managed according to strict rules for non-profit organisations allowing it to act as an independent entity.

- **Main pharmaceutical partner contribution**
  - Annual contribution: 40,000 EUR

- **Small and Medium-sized Enterprise (SME) pharmaceutical partner contribution**
  - Annual contribution: 7,000 EUR

Do I qualify as a small pharmaceutical partner?

The CDDF understands the challenges SMEs face in getting their drugs on the market. We facilitate opportunities to advance drug access and delivery by providing important learning and networking opportunities to help your company streamline the process of making treatment available.

A pharmaceutical partner is considered to be an SME if it has no drug on the market or if it meets the definition of the European Commission for an SME: [https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en](https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en)

If you would like to join the CDDF Industry Partner Platform, please contact us at info@cddf.org

---

BECOME A PARTNER OF THE CDDF

INDUSTRY PARTNER BENEFITS

1. **Access the CDDF Industry Partners Platform** where pharmaceutical partners meet to discuss industry perspectives on the challenges to be addressed in cancer drug development.

2. **3 free registrations to every CDDF event** (one free registration per event for SME partner).

3. **Livestream access** to CDDF workshops and conference on the condition that at least two delegates (or one SME delegate) are present in person at the event.

4. **Early access to digital content** from the conference and workshops for one year before general release.

5. **Contribute to CDDF’s scientific programme** and coordinate event programmes alongside academics and regulators.

6. **Access to a reputable oncology network** and the opportunity to connect informally with representatives from academia, regulatory authorities, HTAs, and patient groups.

---

Do I qualify as a small pharmaceutical partner?

The CDDF understands the challenges SMEs face in getting their drugs on the market. We facilitate opportunities to advance drug access and delivery by providing important learning and networking opportunities to help your company streamline the process of making treatment available.

A pharmaceutical partner is considered to be an SME if it has no drug on the market or if it meets the definition of the European Commission for an SME: [https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en](https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en)
COLLABORATION IS THE KEY TO IMPROVING OUTCOMES FOR CANCER PATIENTS